



*FW*  
Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 18th day of November 2004.

s/ *Christina M. Compelube*  
Christina Compelube

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:  
WESLEY K. M. CHONG, ET AL

Group Art Unit: 1645

Serial No.: 10/776,450

Examiner: TBA

Confirmation No.: 3704

Filed: February 11, 2004

For: ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(b) or 1.97(c)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☒ Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date
10/639,219	08-11-2003
10/783,887	02-20-2004

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: 18 November 2004

Wendy L. Hsu

Wendy L. Hsu  
Attorney For Applicant  
Registration No. 42,794

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4652  
Fax: (858) 678-8233

\*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US 3,810,993	05-14-1974	Basel Dieter Duerr, et al.	
	AB	US 6,114,365	09-05-2000	Paolo Pevarello, et al	
	AC	US 6,262,096	07-17-2001	Sikim Kyoung, et al	
	AD	US 6,569,878	05-27-2003	Wesley K. M. Chong, et al.	
	AE	US 6,720,346	04-13-2004	Shao Song Chu, et al.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AF	FR 1528249	06-19-1967	Ciba-Geigy AG		
	AG	WO 96/14843	05-23-1996	Cor Therapeutics, Inc.		
	AH	WO 97/34876	09-22-1997	Zeneca Limited		
	AI	EP 816362A	01-07-1998	Taisho Pharmaceutical Co., Ltd.		
	AJ	WO 98/04536	02-05-1998	Otsuka Pharmaceutical Company, Limited		
	AK	WO 99/21845	05-06-1999	Agouron Pharmaceuticals Inc.		
	AL	WO 99/24035	05-20-1999	Bristol-Myers Squibb Co.		
	AM	WO 99/62890	12-09-1999	Pfizer Products, Inc.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

-Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AN	WO 00/17175	03-30-2000	Vertex Pharmaceuticals Incorporated		
	AO	WO 00/26202	05-11-2000	Pharmacia & Upjohn S.P.A.		
	AP	WO 00/26203	05-11-2000	Pharmacia & Upjohn S.P.A.		
	AQ	WO 00/75120	12-14-2000	Agouron Pharmaceuticals Inc.		
	AR	WO 01/144241	06-21-2001	Bristol-Myers Squibb Co.		
	AS	WO 01/44242	06-21-2001	Bristol-Myers Squibb Co.		
	AT	WO 02/57261	07-25-2002	F. Hoffmann-La Roche AG		
	AU	WO 03/04467	01-16-2003	Agouron Pharmaceuticals, Inc.		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AV	AKAMA, T., et al., "Synthesis Of An Ethyl 6-Amino-3,5-Difluorosaliclylate Derivative By Sequential Regioselective Directed <i>Ortho</i> -Metalation: A Practical Synthesis of 4',5-Diamino-3',6,8- Trifluoroflavone, A Potent Antitumor Agent," <i>Synthesis</i> , 1997, 1446-1450.	
	AW	BAER, R., et al., "A Novel Solid-Phase Approach To 2,4-Diaminothiazoles," <i>J. Comb. Chem.</i> , 2001, 16-19, vol. 3.	
	AX	BAGSHAW, K., "Antibody-Directed Enzyme Prodrug Therapy: A Review," <i>Drug Development Research</i> , 1995, 220-230, vol. 34.	
	AY	BENNETAU, B., et al., "Fonctionnalisation Regioselective En Position 2 De Benzenes 1,3- Disubstitues," <i>Tetrahedron</i> , 1993, 10843-10854, vol. 49, no. 47.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AZ	BERTOLINI, G., et al., "A New Rational Hypothesis For The Pharmacophore Of The Active Metabolite Of Leflunomide, A Potent Immunosuppressive Drug," <i>J. Med. Chem.</i> , 1997, 2011-2016, vol. 40.	
	BA	BINU, R. et al., "Synthesis And Cyclization Of 1-(N-Nitroamidino) Thioureas To 2,4-Diaminothiazoles," <i>Org. Prep. Proced. Intl.</i> , 1998, 93-96, vol. 30, no. 1.	
	BB	BODOR, N., "Novel Approaches To The Design Of Safer Drugs: Soft Drugs And Site-Specific Chemical Delivery Systems," <i>Advances in Drug Research</i> , 1984, 254-331, vol. 13.	
	BC	BORGEN, R., et al., "Proton Magnetic Resonance Spectra Of Thiazoles," <i>Acta. Chemica Scandinavica</i> , 1966, 2593-2600, vol. 20.	
	BD	BUOLAMWINI, J., "Cell Cycle Molecular Targets In Novel Anticancer Drug Discovery," <i>Current Pharmaceutical Design</i> , 2000, 379-392, vol. 6.	
	BE	CHEMICAL ABSTRACTS, 1969, CIBA Ltd., vol. 71, 263, 30206e.	
	BF	CHEN, G., et al., "Syntheses Of 2,5- and 2,6-Difluoronorepinephrine, 2,5-Difluoroepinephrine, And 2,6-Difluorophenylephrine: Effect Of Disubstitution With Fluorine On Adrenergic Activity," <i>J. Med. Chem.</i> , 1993, 3947-3955, vol. 36.	
	BG	CHUCHANI, G., et al., "Tritylation Of Aminobenzenethiois," <i>J. Chem. Soc. C</i> , 1969, 1436-1437.	
	BH	CREWS, C., et al., "Small-Molecule Inhibitors Of The Cell Cycle," <i>Current Opinion in Chemical Biology</i> , 2000, 47-53, vol. 4.	
	BI	DEAR, G., et al., "Mass Directed Peak Selection, An Efficient Method Of Drug Metabolite Identification Using Directly Coupled Liquid Chromatography-Mass Spectrometry-Nuclear Magnetic Resonance Spectroscopy," <i>Journal of Chromatography B</i> , 2000, 281-293, vol. 748.	
	BJ	DEVI, S., et al., "Synthesis Of 2,4-Diamino-5-(FUR-2-OYL), (THIEN-2-OYL), And (PYRID-2-OYL) Thiazoles," <i>Synthetic Communications</i> , 2002, 1523-1528, vol. 32, no. 10.	
	BK	GEWALD, V., et al., "4-Amino-Thiazole," <i>J. Pract. Chem.</i> , 1967, 97-104, vol. 35.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BL	GRAY, N., et al., "ATP-Site Directed Inhibitors Of Cyclin-Dependent Kinases," <i>Current Medicinal Chemistry</i> , 1999, 859-875, vol. 6.	
	BM	HERNANDEZ, A., et al., "Solid-Supported <i>Tert</i> -Alkoxyacylation Reagents For Anchoring Of Amines During Solid Phase Organic Synthesis," <i>J. Org. Chem.</i> , 1997, 3153-3157, vol. 62.	
	BN	HOSOI, T., et al., "Evidence For cdk5 As A Major Activity Phosphorylating Tau Protein In Porcine Brain Extract," <i>J. Biochem.</i> , 1995, 741-749, vol. 117.	
	BO	JEFFREY, P., et al., "Mechanism Of CDK Activation Revealed By The Structure Of A cyclinA-CDK2 Complex," <i>Nature</i> , 1995, 313-320, vol. 376.	
	BP	JENARDANAN, G., et al., "1-(N-Arylthiocarbamoyl) Amidino-3,5-Dimethyl Pyrazoles-Preparation And Use In Heterocycle Synthesis," <i>Synthetic Communications</i> , 1997, 3457-3462, vol. 27, no. 19.	
	BQ	JONES, T., et al., "Structure-Based Design Of Lipophilic Quinazoline Inhibitors Of Thymidylate Synthase," <i>J. Med. Chem.</i> , 1996, 904-917, vol. 39.	
	BR	JOSHI, K., et al., "Studies In Fluorinated 1,3-Diketones And Related Compounds Part XIII: Synthetic And Spectral Studies Of Some New Fluorinated <i>Tris</i> Europium 1,3-Diketones," <i>J. Indian, Chem. Soc.</i> , 1982, 293-294, vol. 59.	
	BS	KIMBALL, S., et al., "Cell Cycle Kinases And Checkpoint Regulation In Cancer," <i>Ann. Rep. Med. Chem.</i> , 2001, 139-148, vol. 36.	
	BT	KING, C., et al., "Selective Bromination With Copper (II) Bromide," <i>J. Org. Chem.</i> , 1964, 3459-3461, vol. 29.	
	BU	KRAZER, B., et al., "The Nature Of The Bond Between reactive Dyes And Cellulose," <i>Helvetica Chimica Acta</i> , 1960, 1513-1519, vol. 43.	
	BV	KUO, Y., et al., "A New Method For Preparation Of 3-Hydroxypyridines From Furfurylamines By Photooxygenation," <i>Chem. Pharm. Bull.</i> , 1991, 181-183, vol. 39, no. 1.	
	BW	LEE, R., et al., "New Synthetic Cluster Ligands For Galactose/ <i>N</i> -Acetylgalactosamine-Specific Lectin Of Mammalian Liver," <i>Biochemistry</i> , 1984, 4255-4261, vol. 23.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BX	MASQUELIN, T., et al., "A New General Three Component Solution-Phase Synthesis Of 2-Amino-1,3-Thiazole And 2,4-Diamino-1,3-Thiazole Combinatorial Libraries," <i>Tetrahedron</i> , 2001, 153-156, vol. 57.	
	BY	MC KEE, R., et al., "p-Substituted Phenyl Isothiocyanates And Some Related Thioureas," <i>J. Am. Chem. Soc.</i> , 1946, 2506-2507, vol. 68.	
	BZ	MC MORRIS, T., et al., "Improved Synthesis Of Brassinolide," <i>J. Chem. Soc. Perkin Trans. 1</i> , 1996, 295-302.	
	CA	MEIJER, L., et al., "Chemical Inhibitors Of Cyclin-Dependent Kinases," <i>Methods in Enzymology</i> , 1997, 113-128, vol. 283.	
	CB	METZGER, J., et al., "Organometallic Derivatives of Thiazole. II. Organolithium Derivs," <i>Bulletin de la Societe Chimique de France</i> , 1953, 708-709.	
	CC	MLOTKOWSKA, B., et al., "Reactions Of 2,4- And 2,6-Dichlorophenacylidene Halides With Trialkylphosphites In Protic Solvents. Direct Evidence For The "Enolate Anion" Pathway," <i>Polish Journal of Chemistry</i> , 1981, 631-642, vol. 55.	
	CD	MOSMANN, T., et al., "Rapid Colorimetric Assay For Cellular Growth And Survival: Application To Proliferation And Cytotoxicity Assays," <i>Journal of Immunological Methods</i> , 1983, 55-63, vol. 65.	
	CE	PARAST, C., et al., "Characterization And Kinetic Mechanism Of Catalytic Domain Of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), A Key Enzyme In Angiogenesis," <i>Biochemistry</i> , 1998, 16788-16801, vol. 37.	
	CF	PIEPER, H., et al., "Preparation And Biological Activity Of New Substituted Antimalarial Diaminodiphenylsulfones," <i>Arzneim. Forsch.</i> , 1989, 1073-1080, vol. 39, no. II.	
	CG	PROX., A., et al., "Rapid Structure Elucidation Of Drug Metabolites By Use Of Stable Isotopes," <i>Xenobiotica</i> , 1973, 103-112, vol. 3, no. 2.	
	CH	RAJASEKHARAN, K., et al., "Studies On The Synthesis Of 5-Acyl-2,4-Diaminothiazoles From Amidinothioureas," <i>Synthesis</i> , 1986, 353-355.	
	CI	ROSANIA, G., et al., "Targeting Hyperproliferation Disorders With Cyclin Dependent Kinase Inhibitors," <i>Expert Opinion On Therapeutic Patents</i> , 2000, 215-230, vol. 10, no. 2.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
.	CJ	ROSENBLATT, J., et al., "Purification And Crystallization Of Human Cyclin-Dependent Kinase 2," <i>J. Mol. Biol.</i> , 1993, 1317-1319, vol. 230.	
	CK	SCHANG, L., et al., "Roscovitine, A Specific Inhibitor Of Cellular Cyclin-Dependent Kinases, Inhibits Herpes Simplex Virus DNA Synthesis In The Presence Of Viral Early Proteins," <i>Journal Of Virology</i> , 2000, 2107-2120, vol. 74, no. 5.	
	CL	SHAN, D., et al., "Prodrug Strategies Based On Intramolecular Cyclization Reactions," <i>Journal Of Pharmaceutical Sciences</i> , 1997, 765-767, vol. 86, no. 7.	
	CM	SIELECKI, T., et al., "Cyclin-Dependent Kinase Inhibitors: Useful Targets In Cell Cycle Regulation," <i>Journal of Medicinal Chemistry</i> , 2000, 1-18, vol. 43, no. 1.	
	CN	SPRAUL, M., et al., "Liquid Chromatography Coupled With High-Field Proton NMR For Profiling Human Urine For Endogenous Compounds And Drug Metabolites," <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1992, 601-605, vol. 10, no. 8.	
	CO	STILL, W., et al., "Rapid Chromatographic Technique For Preparative Separations With Moderate Resolution," <i>J. Org. Chem.</i> , 1978, 2923-2925, vol. 43, no. 14.	
	CP	STOVER, D., et al., "Recent Advances In Protein Kinase Inhibition: Current Molecular Scaffolds Used For Inhibitor Synthesis," <i>Current Opinion In Drug Discovery</i> , 1999, 274-285, vol. 2, no. 4.	
	CQ	TAKAHASHI, T., et al., "Syntheses Of Heterocyclic Compounds Of Nitrogen LXXXVIII," <i>Pharm. Bull.</i> , 1954, 30-34, vol. 2, no. 1.	
	CR	TOOGOOD, P., et al., "Cyclin-Dependent Kinase Inhibitors For Treating Cancer," <i>Medicinal Research Reviews</i> , 2001, 487-498, vol. 21, no. 6.	
	CS	TOPLISS, J., et al., "Antihypertensive Agents. I. Non-Diuretic 2H-1,2,4-Benzothiadiazine 1,1-Dioxides," <i>J. Med. Chem.</i> , 1963, 122-127, vol. 6.	
	CT	UHER, M., et al., Chemicke Zvesti, 21, 44-56, Chem. Abs. 43495, 1967	
	CU	WEBSTER, K., et al., "The Therapeutic Potential Of Targeting The Cell Cycle," <i>Expert Opinion On Investigational Drugs</i> , 1998, 865-887, vol. 7 no. 6.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



\*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓ ✓	CV	YANO, Y., et al., "Stimulatory Effects Of Lipoprotein(a) And Low-density Lipoprotein On Human Umbilical Vein Endothelial Cell Migration And Proliferation Are Partially Mediated By Fibroblast Growth Factor-2," Biochimica et Biophysica Acta, 1998, 26-34, vol. 1393.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.